- Newsletter to Shareholders
- MEB Appoints R&CPMK as Communications Agency in the US
- Section 708A Cleansing Notice and Appendix 2A
June 2021
May 2021
- Medibio strengthens its IP protection
- Medibio Quarterly Update and Cashflow Report
April 2021
- Re-submission of FDA 510(k) application
- Consumer Mental Health App Development – Second Test Phase
- Appendix 3G
- Section 708A Cleansing Notice and Appendix 2A
- Appendix 2A
- Proposed issue of Securities – MEB (Revised)
- MEB Share Purchase Plan Closes Strongly Oversubscribed
- Supplementary Prospectus
March 2021
- Results of General Meeting
- Annual General Meeting
- Medibio Begins Implementation of ilumen in the United Kingdom
- Medibio To Present at World Forum for Sleep Medicine
- Share Purchase Plan Prospectus
February 2021
- Half Yearly Report and Accounts
- Notice of General Meeting/Proxy Form
- Notice of Change of Interests of Substantial Holder
- Appendix 3G Notification of issue, conversion or payment of Equity + Securities
- Section 708A Cleansing Notice Appendix 2A
- Appendix 3G
- Appendix 3B Proposed issue of + securities
- Underwritten Share Purchase Plan Update
- Investors Presentation FEB 2021
- Appendix 3B Proposed issue of +securities
- Proposed issue of securities – Announcement Summary 2
- Medibio to Raise up to $3.5 million By Way of a Placement and SPP
- Proposed issue of securities – Announcement Summary
- ASX- MEB Trading Halt
- December 2020 Quarterly Activities Report and Appendix 4C
January 2021
- Medibio Granted CE Mark Approval for MEBsleep
- US FDA advises further data needed for MEBsleep approval
- Medibio’s Patent-Protected Consumer Mental Health App, Commences Initial Testing Phase
December 2020
- Updated Capital Structure
- Appendix 3Y Change of Director’s Interest Notice
- Appendix 3G Notification of issue, conversion or payment up of equity + securities
- Release of Securities from Escrow
- Medibio signs Global Master License and Services Agreement with Compass Group Plc. for ilumen
- Medibio Investor Webinar Presentation
- Update on Breakthrough Device Program
November 2020
- RESULTS OF ANNUAL GENERAL MEETING
- Medibio Investor Webinar Presentation
- CHAIRMAN’S ADDRESS ANNUAL GENERAL MEETING
- Amended Constitution
- MEB AGM Presentation
- Notice of Annual General Meeting
October 2020
- Medibio Signs Clinical Trial Agreement With US-based MedBridge Healthcare LLC For its Depressive Burden Trial
- Medibio Submits Request For FDA Breakthrough Device Designation
- Appendix 3G
- Securities Trading Policy
- Updated Capital Structure
- September 2020 Quarterly Activities Report and Appendix 4C
- Notice of Annual General Meeting Proxy Form
- Securities Trading Policy
- Updated Capital Structure
- September 2020 Quarterly Activities Report and Appendix 4C
September 2020
- Medibio Limited – Annual Report – 30 June 2020
- Appendix 4G and Corporate Governance Statement
August 2020
- FDA Strategy and Regulatory Update
- Medibio granted US Patent for Monitoring Stress Conditions Using Heartrate
- Appendix 2A Application for quotation of & securities
- Appendix 4E Preliminary Final Report 30 June 2020
- FDA Strategy & Regulatory Update
July 2020
- Medibio Announces Entitlement Issue Results
- Appendix 2A Application for quotation of + securities
- Appendix 3Y Change of Director’s Interest Notice
- June Quarterly Activities Report and Appendix 4C
June 2020
- Appendix 2A Application for quotation of +securities
-
Appendix 3G Notification of issue, conversion or payment up of equity +securities
- MEB Raises $2m via Placement and Fully Underwritten Entitlement Offer
-
Offer Document Entitlement Issue
- Non-Renounceable Entitlement Offer Cleansing Notice under Section 708AA(2)(F) of the Corporations Act 2001 (Cth)
-
Section 708A Cleansing Notice
-
Investor Presentation
-
Notification to ineligible shareholders of Entitlement Offer
-
Notification of pro-rata non-renounceable Entitlement Issue
-
Notification to eligible shareholders of Entitlement Offer
-
Section 708A Cleansing Notice and Appendix 2A
-
Despatch of Offer Letter to Eligible Shareholders
-
Appendix 3G Notification of issue, conversion or payment up of equity +securities
-
MEB Announces Extension to Entitlement Offer
April 2020
-
Medibio’s ilumen™ supporting the global workforce during COVID-19 health crisis
-
Final Compass Pilot completed successfully
-
Capital Structure Update
-
Medibio Submits FDA 510K Application to the FDA for its Sleep Staging Medical Software Device
-
Quarterly Activities Report and Appendix 4C
March 2020
-
Executive Appointments at Medibio to Support Growth of ilumen™
-
FDA Strategy Update
-
Medibio Signs Memorandum of Understanding with DXC for ilumen™
February 2020
- Strategic Plan for FDA and CE Mark Approval
-
Medibio Signs Annual Services Agreement with Stantec Australia for ilumen™
-
Appendix 4D and Half-Yearly Report for 31 December 2019
January 2020
- Changes to the Board
- Final Director’s Interest Notice
- Letter from the Managing Director
- Quarterly Operations Report and Appendix
April 2020
-
Medibio’s ilumen™ supporting the global workforce during COVID-19 health crisis
-
Final Compass Pilot completed successfully
-
Capital Structure Update
-
Medibio Submits FDA 510K Application to the FDA for its Sleep Staging Medical Software Device
-
Quarterly Activities Report and Appendix 4C
March 2020
-
Executive Appointments at Medibio to Support Growth of ilumen™
-
FDA Strategy Update
-
Medibio Signs Memorandum of Understanding with DXC for ilumen™
February 2020
- Strategic Plan for FDA and CE Mark Approval
-
Medibio Signs Annual Services Agreement with Stantec Australia for ilumen™
-
Appendix 4D and Half-Yearly Report for 31 December 2019
January 2020
- Changes to the Board
- Final Director’s Interest Notice
- Letter from the Managing Director
- Quarterly Operations Report and Appendix
April 2020
-
Medibio’s ilumen™ supporting the global workforce during COVID-19 health crisis
-
Final Compass Pilot completed successfully
-
Capital Structure Update
-
Medibio Submits FDA 510K Application to the FDA for its Sleep Staging Medical Software Device
-
Quarterly Activities Report and Appendix 4C
March 2020
-
Executive Appointments at Medibio to Support Growth of ilumen™
-
FDA Strategy Update
-
Medibio Signs Memorandum of Understanding with DXC for ilumen™
February 2020
- Strategic Plan for FDA and CE Mark Approval
-
Medibio Signs Annual Services Agreement with Stantec Australia for ilumen™
-
Appendix 4D and Half-Yearly Report for 31 December 2019
January 2020
- Changes to the Board
- Final Director’s Interest Notice
- Letter from the Managing Director
- Quarterly Operations Report and Appendix
December 2019
- Report to Shareholders and Outlook for 2020
- Appendix 3G: Notification of issue, conversion or payment up of equity +securities
- Appendix 3Y: Change of Director’s Interest Notice
November 2019
- Results of Annual General Meeting
- Company Update
- Final Directors Interest Notice
October 2019
- Medibio Provides Updated Securities Trading Policy
- Medibio Successfully Completes First Pilot with Compass Group
- Medibio Notice of Annual General Meeting and Proxy Form
- Notice of Ceasing to be a Substantial Holder
- Medibio CEO to Participate on Panel at Garmin Digital Health Summit APAC
- Medibio Signs Agreement with PwC Australia for ilumen™
- Quarterly Update and Appendix 4C 31 October 2019
September 2019
- Withdrawal of Notice of Initial Substantial Shareholding
- Becoming A Substantial Holder 2 Sept 2019
- Change in Substantial Holding 3 Sept 2019
- Cleansing Notice 4 September 2019
- Change of Directors Interest 4 Sept 2019
- Initial Directors Interest 4 Sept 2019
- Medibio Announces Results of Review of Partly Paid Shares
- Medibio Appendix 4G and Governance Statement
- Medibio 2019 Annual Report
August 2019
- Medibio Supplementary Prospectus
- Medibio Results of August 2019 AGM
- Medibio Appendix 3B 20 August 2019
- Medibio Completes Oversubscribed Share Purchase Plan
- Medibio ASX Information for New Quoted Option Class
- Medibio Appendix 3B 29 August 2019
- Medibio Announces New Board Members and Establishes Growth & Advocacy Advisory Board
- Medibio Announces Fourth Pilot Agreement with Compass Group
- Medibio Appendix 4E Preliminary Report
- Medibio Becoming a Substantial Holder 30 Aug 2019
- Medibio Appendix 3B 30 Aug 2019
- Medibio Final Directors Notice 30 Aug 2019
July 2019
- Medibio Signs Global Organisation, Compass Group PLC, for the First of Two UK-based Pilots for ilumen™
- Medibio Requests Trading Halt in Relation to Capital Raising
- Medibio Suspension from Official Quotation
- Medibio Reinstatement to Official Quotation
- Medibio Raises $4,020,000 By Way of a Placement and Fully Underwritten SPP
- Medibio Signs Second Compass Group PLC Pilot for ilumen™
- Medibio Notice of Extraordinary General Meeting, Explanatory Statement and Proxy Form
- Medibio Notice of Change of Interest of Substantial Holder
- Medibio Prospectus Offer of Options and Shares for SPP
- Medibio Appendix 3B
- Medibio Partners with Digital Corporate Wellness Solution Leader WellteQ
- Medibio Signs Compass Group Australia for Corporate Health Product ilumen™
- Medibio Quarterly Operations Report and Appendix 4C
June 2019
- Appendix 3B New Issue Announcement
- Joint Venture Dispute
- Change of Directors Notice
- Medibio Algorithm Validated in Study Published in Peer Reviewed Journal
May 2019
- Medibio Provides Updated Investor Deck
- Medibio Results of General Meeting
- Medibio Response to ASX 4C Query
- Medibio Provides Updated Investor Deck 27 May 2019
April 2019
- Medibio Provides Notice of General Meeting
- Medibio Announces Sponsored Research Agreement with Humanitas
- Medibio Announces Revised Regulatory and Commercialisation Strategy
- Medibio Provides Quarterly Message and Appendix 4C
March 2019
- Medibio Corporate Health Product ilumen™ Successfully Completes First Commercial Program
- Medibio Announces Entitlement Issue Results and Shortfall Notification
- Medibio Outsources Psychology Services in Support of Corporate Health Product ilumen™
- Medibio Announces Completion of Entitlement Issue
- Medibio Shareholder Update & Outlook
- Medibio Provides Updated Investor Presentation
February 2019
- Medibio Extension of Entitlement Offering
- Medibio Investor Presentation
- Medibio Announces Changes to Board of Directors and Appointment of Chairman
- Medibio Announces Extension to Entitlement Offer
- Medibio Correction to Extension of Entitlement Offer
- Medibio Appendix 4D Half Year Report
January 2019
- Medibio Results of January 2019 General Meeting
- Medibio Cleansing Notice and Appendix 3B
- Medibio Quarterly Update & Cash Flow
December 2018
- Medibio Requests Trading Halt
- Medibio Converting Note & Non-Renounceable Entitlement Offer
- Medibio Section 708AA(2)(F) Cleansing Statement and Appendix 3B
- Medibio Updated Investor Presentation December 10, 2018
- Medibio Notification of Pro-Rata Non-Renounceable Entitlement Issue
- Medibio Letter to Shareholders Entitlement Offer
- Medibio Letter to Ineligible Shareholders Entitlement Offer
- Medibio Rights Issue Offer Document
- Medibio Notice of General Meeting
- Medibio Announces Changes to the Board of Directors and Cost Reduction Plans
November 2018
- Medibio Market Update
- Medibio Appoints Global Healthcare & Medical Device Leader as CEO and Managing Director
- Medibio Provides Update on FDA Process
- Medibio Provides Chairman’s Address to Shareholders
- Medibio Announces Appointment of Joint Corporate Secretary
- Medibio Releases Results of Annual General Meeting
- Medibio Signs Insurance Company AIA Australia Ltd (AIAA) For an Exclusive Pilot Program For ilumen™
- Medibio Provides Updated Investor Deck
October 2018
- Notice Received Under Section 249D of the Corporations Act
- Medibio Releases Corporate Health Product, ilumen™
- Medibio Updates Company Presentation
- Medibio Technology Honored with Two Presentations at Mayo Clinic Convergence Neuroscience 2018
- Medibio Receives R&D Tax Incentive Refund
- Medibio Notice of Annual General Meeting
- Medibio Signs ilumen™ Corporate Contract with a Large Australian Employer
- Medibio Quarterly & Cash Flow Report
September 2018
-
Medibio Clinical Study Shows Over 20% Improvement to Current Diagnostic Standard
- Medibio Hosts Call to Discuss Clinical Validation Study
- Medibio Market Update
- Medibio Releases Appendix 4G & Corporate Governance Statement
- Medibio Releases Financial Report for the Year Ended 30 June 2018
- Medibio Announces Executive Leadership Changes
August 2018
-
Medibio announces change in senior management
July 2018
-
Medibio Submits FDA De Novo Application
- Medibio to announce fourth quarter FY18 results
- Quarterly Update and Message from CEO of Medibio Limited
June 2018
-
Appointment and Resignation of Company Secretary And Change of Registered Office Address
- Medibio provides updated Investor Presentation
- Medibio to Provide Corporate Health Investor Presentation
- Medibio Receives TGA Approval
- Peer-reviewed Neurology Publication on Medibio Science
May 2018
- Medibio Announces Global Launch – Corporate Mental Health For Business
- Medibio Receives CE Certification
- Medibio Corporate Health contract signed with Australia’s 3rd largest private healthcare provider
- Medibio Launches Personal Mental Health Measurement App for Apple Watch
- Medibio Announces Next Tranche of Corporate Health Contracts
- Medibio Corporate Health Signs Global Contract with Jacobs Engineering
April 2018
- Medibio finalizes acquisition of Vital Conversations
- Medibio Announces Scientific Advisory Board
- Medibio to announce third Quarter FY18 update and cashflow
- Quarterly ASX Update and Cashflows
January 2018
-
Peter Carlisle Appointed as Director
- Medibio Investor Conference Call Announcement
- Australia – 1st February
- U.S. – January 31st
December 2017
-
U.S. Department of Veterans Affairs White River Junction Medical Center Joins Medibio Depression Diagnostic Confirmatory Study to Support FDA Clearance
-
Mayo Clinic to begin Prospective Clinical Study with Medibio Technology for Expanded Market Opportunities
November 2017
October 2017
August 2017
July 2017
June 2017
May 2017
April 2017
March 2017
February 2017
January 2017
December 2016
November 2016
October 2016
- App 3B (7 Oct 2016)
- Funding Update (10 Oct 16)
- MEB Annual 2016 (10 Oct 2016)
- Partners with HBF and Vital Conversation (11 Oct 2016)
- MEB R & D Tax Incentive Refund
- Notice of Annual General Meeting (28 Oct 2016)
- Medibio Shareholder Newsletter (28 Oct 2016)
- App 3B (28 Oct 2016)
- Quarterly report (31 Oct 2016)
- Quarterly Cash Flow Report (30 Oct 2016)
September 2016
August 2016
July 2016
June 2016
May 2016
April 2016
March 2016
February 2016
January 2016
December 2015
November 2015
- MEB Quarterly Report for the period ending (30 Sep 2015)
- MEB’s Signs First Multinational Client (6 Nov 2015)
- MEB Foster Research Report (10 Nov 2015)
- MEB ASX Investor Series Presentation (17 Nov 2015)
- MEB Final JHU Release-IRB (ASX Release) (24 Nov 2015)
- MEB Corporate Wellness Partner Program Commences (26 Nov 2015)
October 2015
September 2015
August 2015
July 2015
May 2015
April 2015
- Medibio Investor Presentation (April 2015)
- Completion of Restructure (2 April 2015)
- Distinguished Clinician Dr Frank Prendergast joins MEB (12 April 2015)
- U.S. Patent (21 April 2015)
March 2015
February 2015
January 2015
December 2014
November 2014
October 2014
July 2014
June 2014
May 2014
April 2014
March 2014
February 2014
January 2014
Archived Announcements
November
Frontier Oil Corporation Shareholder Update
Appendix 3Z Director Final Interest
Appendix 3X Director Initial Interest
Appointments of New Director & Chairman
Results of Annual General Meeting
October
Frontier Oil Corporation IPO Approval
Notice of Annual General Meeting/Proxy Form
September
Convertible Note Restructure Clarification
August
July
April
Corporate Governance Policy Update
February
Half-Yearly Report to 31 December 2013
Update on Frontier Oil Investment